参考文献/References:
[1].Tai D,Wells K,Arcaroli J,et al. Targeting the WNT signaling pathway in cancer therapeutics[J]. Oncologist,2015,20(10):1189-1198.
[2].Gay A,Towler DA. Wnt signaling in cardiovascular disease:opportunities and challenges[J]. Curr Opin Lipidol,2017,28(5):387-396.
[3].Sebastian A,Hum NR,Murugesh DK,et al. Wnt co-receptors Lrp5 and Lrp6 differentially mediate Wnt3a signaling in osteoblasts[J]. PLoS One,2017,12(11):e0188264.
[4].Fuster JJ,Zuriaga MA,Ngo DT,et al. Noncanonical Wnt signaling promotes obesity-induced adipose tissue inflammation and metabolic dysfunction independent of adipose tissue expansion[J]. Diabetes,2015,64(4):1235-1248.
[5].Frey JL,Kim SP,Li Z,et al. β-catenin directs long-chain fatty acid catabolism in the osteoblasts of male mice[J]. Endocrinology,2018,159(1):272-284.
[6].Srivastava R,Zhang J,Go GW,et al. Impaired LRP6-TCF7L2 activity enhances smooth muscle cell plasticity and causes coronary artery disease[J]. Cell Rep,2015,13(4):746-759.
[7].Ramachandran B,Stabley JN,Cheng SL,et al. A GTPase-activating protein binding protein (G3BP1) / antiviral protein relay conveys arteriosclerotic Wnt signals in aortic smooth muscle cells[J]. J Biol Chem,2018,293(21):7942‐7968.
[8].Foer D,Zhu M,Cardone RL,et al. Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis[J]. Osteoporos Int,2017,28(6):2011-2017.
[9].Karczewska-Kupczewska M,Stefanowicz M,Matulewicz N,et al. Wnt signaling genes in adipose tissue and skeletal muscle of humans with different degree of insulin sensitivity[J]. J Clin Endocrinol Metab,2016,101(8):3079-3087.
[10].Janssen LGM,van Dam AD,Hanssen MJW,et al. Higher Plasma Sclerostin and Lower Wnt Signaling Gene Expression in White Adipose Tissue of Prediabetic South Asian Men Compared with White Caucasian Men.[J]. Diabetes Metab J,2020,44(2):326‐335.
[11].Palsgaard J,Emanuelli B,Winnay JN,et al. Cross-talk between insulin and Wnt signaling in preadipocytes:role of Wnt co-receptor low density lipoprotein receptor-related protein-5 (LRP5)[J]. J Biol Chem,2012,287(15):12016‐12026.
[12].Chang YC ,Hsu BG,Liou HH,et al. Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients[J]. BMC Cardiovasc Disord,2018,18(1):214.
[13].[13] Vallerie SN,Furuhashi M,Fucho R,et al. Correction:a predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity[J]. PLoS One,2008,3(9):e3151.
[14].Tong S,Ji Q,Du Y,et al. Sfrp5/Wnt pathway:a protective regulatory system in atherosclerotic cardiovascular disease[J]. J Interferon Cytokine Res,2019,39(8):472-482.
[15].Tang QQ,Lane MD. Adipogenesis:from stem cell to adipocyte[J]. Annu Rev Biochem,2012,81:715‐736.
[16].Wang X,Peng Q,Jiang F,et al. Secreted frizzled-related protein 5 protects against oxidative stress-induced apoptosis in human aortic endothelial cells via downregulation of Bax[J]. J Biochem Mol Toxicol ,2017,31(12).DOI:10.1002/jbt.21978.
[17].Mizutani M,Wu JC,Nusse R. Fibrosis of the neonatal mouse heart after cryoinjury is accompanied by Wnt signaling activation and epicardial-to-mesenchymal transition[J]. J Am Heart Assoc,2016,5(3):e002457.
[18].Ye B,Ge Y,Perens G,et al. Canonical Wnt/β-catenin signaling in epicardial fibrosis of failed pediatric heart allografts with diastolic dysfunction[J]. Cardiovasc Pathol,2013,22(1):54-57.
[19].Zhang M,Hagenmueller M,Riffel JH,et al. Calcium/calmodulin-dependent protein kinaseⅡcouples wnt signaling with histone deacetylase 4 and mediates dishevelled-induced cardiomyopathy[J]. Hypertension,2015,65(2):335-344.
[20].Formiga FR,Pelacho B,Garbayo E,et al. Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration[J]. J Control Release ,2014,173:132-139.
[21].常文婧,王丽娜. Hippo通路在心脏发育、再生和疾病中的作用[J]. 心血管病学进展,2019,40(8):1115-1118.
[22].Patel KM,Strong A,Tohyama J,et al. Macrophage sortilin promotes LDL uptake,foam cell formation,and atherosclerosis[J]. Circ Res,2015,116(5):789-796.
[23].Bogdanovich S,Kim Y,Mizutani T,et al.Human IgG1 antibodies suppress angiogenesis in a target-independent manner[J]. Signal Transduct Target Ther,2016,1:15001.
[24].Du J,Li J. The role of Wnt signaling pathway in atherosclerosis and its relationship with angiogenesis[J]. Exp Ther Med,2018,16(3):1975-1981.
[25].Kim J,Kim J,Kim DW,et al. Wnt5a induces endothelial inflammation via β-catenin-independent signaling[J]. J Immunol,2010,185(2):1274-1282.
[26].Kozinski K,Jazurek M,Dobrzyn P,et al. Adipose- and muscle-derived Wnts trigger pancreatic β-cell adaptation to systemic insulin resistance[J]. Sci Rep,2016,6:31553.
[27].[27] Yan J Y,Zhou Q,Yu H M,et al.High glucose promotes vascular smooth muscle cell calcification by activating WNT signaling pathway[J].Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2015, 35(1):29-33.
[28].[28] Williams H,Mill CA,Monk BA,et al. Wnt2 and WISP-1/CCN4 induce intimal thickening via promotion of smooth muscle cell migration[J]. Arterioscler Thromb Vasc Biol,2016,36(7):1417-1424.
相似文献/References:
[1]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(8):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[2]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(8):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[3]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(8):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[4]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(8):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[5]曹岩 颜培实.残余胆固醇与动脉粥样硬化性心血管疾病[J].心血管病学进展,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
CAO Yan,YAN Peishi.Remnant Cholesterol And Atherosclerotic?ardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(8):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
[6]蔡薇 杨堰焯 刘昊凌.甘油三酯葡萄糖乘积指数与糖尿病血管病变的研究进展[J].心血管病学进展,2022,(3):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
CAI Wei,YANG Yanzhuo,LIU Haoling.Triglyceride-Glucose Index and Diabetic Vascular Disease[J].Advances in Cardiovascular Diseases,2022,(8):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[7]陈林滔 田清平 刘梅林.残余胆固醇预测动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2022,(6):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
CHEN Lintao,TIAN Qingping,LIU Meilin.Remnant Cholesterol in Predicting Atherosclerotic Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2022,(8):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
[8].胆固醇酯转移蛋白抑制剂在动脉粥样硬化性心血管疾病治疗中的研究进展[J].心血管病学进展,2022,(7):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
ZHU Jie,GAO Fen,XUE Shuanqin,et al.Treatment of Atherosclerotic Cardiovascular Diseases with Cholesteryl Ester Transfer Protein Inhibitor[J].Advances in Cardiovascular Diseases,2022,(8):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[9]欧阳运峰 李皇庆 李璐 阳军.脂蛋白a：动脉粥样硬化性心血管疾病防治新靶点[J].心血管病学进展,2022,(8):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]
OUYANG Yunfeng,LI Huangqing,LI Lu,et al.Lipoprotein A:a New Target for Prevention and Treatment of Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(8):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]
[10]安海英 涂建成.载脂蛋白B与非高密度脂蛋白胆固醇在ASCVD防控中的应用价值[J].心血管病学进展,2022,(9):803.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.009]
AN Haiying,TU Jiancheng.Application Value of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol in ASCVD Prevention and Control[J].Advances in Cardiovascular Diseases,2022,(8):803.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.009]